Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More
BH.IMMUN&BIO ACTAVIS |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
BH.IMMUN&BIO Mar-23 |
ACTAVIS Dec-18 |
BH.IMMUN&BIO/ ACTAVIS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 52 | 16,126 | - | |
Low | Rs | 21 | 10,818 | - | |
Sales per share (Unadj.) | Rs | 10.3 | 3,955.8 | - | |
Earnings per share (Unadj.) | Rs | -3.9 | -1,274.2 | - | |
Cash flow per share (Unadj.) | Rs | -3.8 | 416.9 | - | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 20.4 | 16,315.7 | - | |
Shares outstanding (eoy) | m | 43.18 | 332.60 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 3.5 | 3.4 | 102.7% | |
Avg P/E ratio | x | -9.4 | -10.6 | 88.7% | |
P/CF ratio (eoy) | x | -9.5 | 32.3 | -29.4% | |
Price / Book Value ratio | x | 1.8 | 0.8 | 214.3% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 1,561 | 4,480,758 | 0.0% | |
No. of employees | `000 | NA | 16.9 | 0.0% | |
Total wages/salary | Rs m | 151 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 77,851.4 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | -25,076.0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 446 | 1,315,689 | 0.0% | |
Other income | Rs m | 11 | 25,160 | 0.0% | |
Total revenues | Rs m | 457 | 1,340,849 | 0.0% | |
Gross profit | Rs m | -161 | 34,478 | -0.5% | |
Depreciation | Rs m | 2 | 562,428 | 0.0% | |
Interest | Rs m | 71 | 75,923 | 0.1% | |
Profit before tax | Rs m | -223 | -578,713 | 0.0% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 147,595 | 0.0% | |
Tax | Rs m | -56 | -7,334 | 0.8% | |
Profit after tax | Rs m | -166 | -423,784 | 0.0% | |
Gross profit margin | % | -36.0 | 2.6 | -1,374.6% | |
Effective tax rate | % | 25.3 | 1.3 | 1,994.7% | |
Net profit margin | % | -37.3 | -32.2 | 115.8% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 358 | 539,627 | 0.1% | |
Current liabilities | Rs m | 940 | 477,372 | 0.2% | |
Net working cap to sales | % | -130.6 | 4.7 | -2,759.1% | |
Current ratio | x | 0.4 | 1.1 | 33.7% | |
Inventory Days | Days | 85 | 20 | 436.3% | |
Debtors Days | Days | 1,135 | 66 | 1,712.2% | |
Net fixed assets | Rs m | 1,262 | 148,929 | 0.8% | |
Share capital | Rs m | 432 | 0 | - | |
Net worth | Rs m | 882 | 5,426,601 | 0.0% | |
Long term debt | Rs m | 0 | 1,910,903 | 0.0% | |
Total assets | Rs m | 1,620 | 8,483,012 | 0.0% | |
Interest coverage | x | -2.2 | -6.6 | 32.5% | |
Debt to equity ratio | x | 0 | 0.4 | 0.0% | |
Sales to assets ratio | x | 0.3 | 0.2 | 177.6% | |
Return on assets | % | -5.9 | -4.1 | 144.2% | |
Return on equity | % | -18.9 | -7.8 | 241.5% | |
Return on capital | % | -17.2 | -4.8 | 356.1% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 109 | 470,046 | 0.0% | |
From Investments | Rs m | 5 | 258,229 | 0.0% | |
From Financial Activity | Rs m | -147 | -806,740 | 0.0% | |
Net Cashflow | Rs m | -34 | -78,073 | 0.0% |
Compare BH.IMMUN&BIO With: MYLAN (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Compare BH.IMMUN&BIO With: RAJNISH WELLNESS LINK PHARMA GUJ.INJ(KER) NUTRAPLUS PR SMRUTHI ORGANICS
After opening the day on high, Indian share markets reversed the trend as the session progressed and ended the lower.